Hughes Steven George, Chief Medical Officer, has demonstrated a clear selling bias in his recent insider transactions, with all 12 of his latest trades involving dispositions of stock in Avidity Biosciences (RNA). His total sell activity amounts to $4.45 million, far outweighing his $666,752 in buy transactions. The most significant sales occurred on August 6, 2025, when he sold shares worth $1.45 million, $755,040, $263,561, and $527,122 in separate transactions, alongside smaller dispositions throughout late 2025 and early 2026. Notably, his January 2026 sales totaled $208,511 and $146,132, reinforcing the sustained selling trend.
While Hughes has engaged in some market purchases ("M" coded transactions), these were comparatively minor, with the largest being a $179,497 acquisition on August 6, 2025, coinciding with his major sales. His activity in RNAM (Avidity Biosciences’ non-voting stock) appears limited to dispositions ("D" coded) on February 27, 2026, though these transactions carried no reported value. The pattern suggests a consistent reduction in his holdings, particularly in RNA, with no recent purchases to offset the sales. The absence of buys in the past year indicates a shift toward divestment rather than accumulation.
AI-assisted summary